论文部分内容阅读
对９０例慢性乙型肝炎进行治疗和随访。治疗Ⅰ组为Ａｒａ—ＡＭＰ＋胸腺素；治疗Ⅱ组为Ａｒａ—ＡＭＰ＋乙肝疫苗；第Ⅲ组为对照组。治疗结束及治疗结束３个月时ＨＢｅＡｇ阴转率：治疗Ⅰ组为４０％为４２％：治疗Ⅱ组为３６．７％和４８％；对照组为１３．３％和１２％。ＨＢＶ—ＤＮＡ阴转辜分别为４６．１％和５５．８％，４８％和５６％及２０％和２４的。与对照组相比，两个治疗组ＨＢｅＡｇ和ＨＢＶ—ＤＮＡ阴转率，除治疗Ⅱ组在治疗结束时ＨＢｅＡｇ阴转率外．其余均有统计学意义。治疗组两种治疗方案无显著差别．对ＨＢｓＡｇ阴转无明显作用。两个用Ａｒａ—ＡＭＰ的治疗组均未出现严重毒副反应。
Ninety patients with chronic hepatitis B were treated and followed up. The treatment group Ⅰ was Ara-AMP + thymosin; the treatment group Ⅱ was Ara-AMP + hepatitis B vaccine; the group Ⅲ was the control group. HBeAg negative conversion rate at the end of treatment and 3 months after the end of treatment: 42% in 40% of treatment group I: 36.7% and 48% in treatment group II and 13.3% and 12% in control group. HBV-DNA negative transgressions were 46.1% and 55.8%, 48% and 56%, respectively, and 20% and 24%. Compared with the control group, HBeAg and HBV-DNA negative conversion rates in the two treatment groups, except for treatment group II HBeAg negative conversion rate at the end of treatment. The rest were statistically significant. There was no significant difference between the two treatment regimens in the treatment group. Negative effect on HBsAg no significant effect. None of the two Ara-AMP treated groups experienced any serious side effects.